10-Q: Inhibikase Q3 loss widens as PAH trial nears

Inhibikase reported a larger Q3 net loss as it ramps spending ahead of a Phase 2b PAH trial, ending the quarter with $77.3 million in cash and securities and targeting a Q4 2025 study start.

Summary

• Ended Q3 2025 with cash, cash equivalents and marketable securities of $77.3 million (cash $38.27m; marketable securities $39.05m).
• Q3 2025 net loss was $11.93 million (vs. $5.78m in Q3 2024); YTD net loss was $35.52 million (vs. $15.39m YTD 2024).
• Q3 2025 operating expenses rose to $12.77 million (vs. $5.83m), driven by higher R&D ($7.65m) and SG&A ($5.61m).
• Nine-month 2025 operating expenses were $38.20 million, including a non-cash $7.36 million IPR&D write-off from the CorHepta acquisition and $10.78 million of stock-based compensation.
• Interest income increased to $0.84 million in Q3 and $2.67 million YTD, reflecting higher invested balances.
• Phase 2b IMPROVE-PAH (approx. 150 patients, 1:1:1 randomization to 300 mg, 500 mg IKT-001 or placebo for 26 weeks) remains on track to initiate in Q4 2025; primary endpoint is change in PVR at Week 26.
• Entered CRO and supply commitments for IMPROVE-PAH: $24.8 million CRO agreement (Aug 8, 2025) and $6.5 million clinical supply agreement (July 1, 2025).
• Completed acquisition of CorHepta on February 21, 2025; accounted as an asset acquisition, with $7.36 million IPR&D expense and contingent consideration liability remeasured to $2.42 million at quarter-end.
• Outlicensed risvodetinib (IKT-148009) to ABLi on May 5, 2025 for $1 upfront, up to $47.5 million in milestones and double-digit royalties; ABLi bears development costs.
• Maintains an at-the-market program with Jefferies for up to $200 million (no sales to date); estimates liquidity is sufficient for at least 12 months from issuance.

Sentiment

Score: 5

Explanation: Operational progress toward Phase 2b is balanced by significantly higher operating losses and continued reliance on external capital; liquidity is adequate for near-term execution.

Positives

• Cash, cash equivalents and marketable securities of $77.3 million provide at least 12 months of runway from issuance.
• Regulatory clearance to initiate Phase 2b in PAH and a finalized protocol targeting clinically meaningful reduction in PVR with interim DSMB safety review at 12 weeks.
• Structured trial execution with CRO ($24.8m, through 2027) and supply ($6.5m, through 2029) agreements in place.
• Interest income rose to $0.84 million in Q3 and $2.67 million YTD, partially offsetting operating spend.
• Change in fair value of contingent consideration produced expense credits of $0.49 million in Q3 and $2.02 million YTD.
• Outlicense of risvodetinib to ABLi introduces up to $47.5 million in development/regulatory milestones plus double-digit royalties, with minimal near-term cash burn.
• Office lease expired September 30, 2025, eliminating right-of-use asset and lease liability; security deposit refund (~$25k) expected in H1 2026.
• Shelf S-3 effective June 27, 2025 and a $200 million ATM with Jefferies adds financing flexibility.

Negatives

• Q3 net loss widened to $11.93 million (from $5.78m) and YTD net loss to $35.52 million (from $15.39m), reflecting accelerated spend.
• R&D expenses increased to $7.65 million in Q3 and $23.43 million YTD, including a non-cash $7.36 million IPR&D charge related to CorHepta.
• SG&A rose materially to $5.61 million in Q3 and $16.78 million YTD, driven by personnel/severance and $10.78 million in YTD stock-based compensation.
• Stockholders’ equity declined to $72.90 million (from $94.87m at 12/31/24) and accumulated deficit increased to $129.95 million.
• Significant equity overhang with outstanding pre-funded and other warrants (e.g., 19.67 million pre-funded warrants outstanding at 9/30/25) and a large option overhang, implying potential future dilution.

Risks

• Government shutdown and potential FDA/SEC staffing disruptions could delay reviews, inspections, meetings or market access activities, adversely affecting development timelines.
• Healthcare policy changes (including the Inflation Reduction Act and executive orders on drug pricing) may pressure pricing, reimbursement and commercialization economics.
• Reliance on third-party manufacturers located in China exposes the company to geopolitical, tariff and data-transfer restrictions that could disrupt supply chains and increase costs.
• Patent scope, validity and enforceability are uncertain; co-owned and in-licensed IP (including prior Sphaera assets transitioned to Pivot) could limit exclusive rights or enforcement.
• U.S. tax law changes (e.g., OBBBA) and Section 174 capitalization may affect cash flows and tax positions.
• Dependence on additional capital raises; potential warrant exercise proceeds may not be timely or available, and financing may not occur on favorable terms.

Future Outlook

Plans to initiate the Phase 2b IMPROVE-PAH study in Q4 2025 with approximately 150 patients across up to 120 sites, including a 12-week DSMB safety review. Continues interactions with the FDA on Phase 3 strategy and expects to apply for Orphan Drug Designation for IKT-001 after required preclinical work. Management believes current liquidity is sufficient for at least 12 months, but additional capital may be needed thereafter; potential warrant exercises may not be timely or available.

Management Comments

• IKT-001 is positioned to be evaluated as a disease-modifying treatment for PAH, leveraging improved tolerability relative to historical imatinib use and updated standards of care.
• The IMPROVE-PAH trial is designed with PVR as the primary endpoint and includes key functional and biomarker secondary endpoints to inform Phase 3 planning.
• Outlicensing risvodetinib to ABLi allows focus on PAH while preserving potential milestone and royalty economics.
• Liquidity of approximately $77.3 million is expected to fund operations for at least the next 12 months from issuance.

Industry Context

PAH remains an orphan market (~$7.66 billion in 2023, projected 3.3% CAGR through 2034) with renewed focus on anti-proliferative pathways following Merck’s WINREVAIR (sotatercept) launch and rapid uptake. IKT-001 targets similar vascular remodeling biology via PDGFR/c-KIT inhibition as a prodrug of imatinib, seeking to improve tolerability; earlier imatinib trials showed efficacy signals but faced safety/tolerability limitations under prior standards of care.

Comparison to Industry Standards

• Merck’s sotatercept (WINREVAIR) has set a new benchmark for additive benefit on top of standard-of-care; IKT-001’s focus on PVR and 6MWD aligns with accepted hemodynamic and functional endpoints used across PAH studies.
• Gossamer Bio’s seralutinib (PDGFR/CSF1R/FLT3 inhibitor) targets anti-proliferative pathways; IKT-001’s systemic prodrug approach for imatinib provides a mechanistic parallel but with differentiated tolerability ambitions and dosing informed by bioequivalence data.
• Prior imatinib Phase 3 (IMPRES) demonstrated efficacy but was limited by safety and discontinuations; IKT-001 is designed to address tolerability while current standards of care and trial designs may mitigate prior risks.

Corporate Governance

Legal Proceedings

• No material litigation or legal proceedings are currently pending.

Related Party Transactions

• No related party vendor expenses were incurred during the three and nine months ended September 30, 2025; in the prior year period, related party R&D vendor expenses were approximately $149,000 (Q3 2024) and $446,000 (YTD 2024), with ~$10,000 payable at 12/31/2024.

Stakeholder Impact

• Shareholders: Significant potential dilution from outstanding pre-funded and other warrants and increased option grants; equity base rose following the October 2024 financing.
• Employees: Expanded equity plan and large option grants increase retention incentives but raise non-cash expense.
• Patients/Investigators: IMPROVE-PAH study initiation in Q4 2025 offers access to a novel PAH therapy under investigation.
• Suppliers/CROs: Long-dated CRO and supply agreements provide revenue visibility to counterparties; $1.0 million retainer prepaid to CRO.
• Regulators: Government shutdown and staffing changes at FDA/SEC could affect timelines and interactions.

Next Steps

• Initiate Phase 2b IMPROVE-PAH in Q4 2025 across up to 120 sites.
• Conduct a 12-week DSMB safety review after at least 50 patients have reached the interim timepoint.
• Continue FDA interactions to define Phase 3 strategy in PAH.
• Apply for Orphan Drug Designation for IKT-001 once required preclinical work is complete.
• Execute on CRO and supply agreements to support trial operations through 2027–2029.
• Evaluate financing options, including potential use of the Jefferies ATM.

Key Dates

Recommendation

The company is appropriately capitalized for near-term execution and is advancing a potentially disease-modifying PAH program into Phase 2b, but operating losses are rising, non-cash charges and stock-based compensation are significant, and additional capital will likely be required beyond 12 months. With key clinical readouts and warrant exercises as future catalysts, a neutral stance is warranted pending Phase 2b execution and safety data.

Keywords

Inhibikase, IKT-001, Pulmonary Arterial Hypertension, PAH, Phase 2b, IMPROVE-PAH, imatinib prodrug, PVR, clinical trial, CorHepta acquisition, ABLi license, risvodetinib, ATM, private placement, warrants, Jefferies, orphan drug designation, FDA, sotatercept, seralutinib